In this study, serum SV2A levels were significantly lower in cognitively unimpaired APOE ε4 carriers than in cognitively unimpaired non-carriers before and after adjusting for age and sex, suggesting that serum SV2A levels had already decreased during the preclinical phase of AD. Here, SV2A is linked to Alzheimer disease.